97 related articles for article (PubMed ID: 34996935)
21. Pirfenidone prevents esophageal stricture by inhibiting nucleotide binding oligomerization domain like receptor protein 3 inflammasome activation.
Hirano S; Higashimori A; Nagami Y; Nadatani Y; Tanigawa T; Ominami M; Fukunaga S; Otani K; Hosomi S; Tanaka F; Kamata N; Taira K; Watanabe T; Fujiwara Y
J Gastroenterol Hepatol; 2022 Jun; 37(6):1096-1106. PubMed ID: 35434849
[TBL] [Abstract][Full Text] [Related]
22. Risk factors and prediction of bleeding after gastric endoscopic submucosal dissection in patients on antithrombotic therapy: newly developed bleeding prediction application software, SAMURAI model.
Hakoda A; Takeuchi T; Kojima Y; Fujiwara Y; Nagami Y; Naito Y; Fukuda S; Koike T; Sugimoto M; Hamada K; Kobara H; Yoshida N; Inaba T; Nagahara A; Koizumi E; Murakami K; Furuta T; Ogasawara N; Isomoto H; Shibagaki K; Kataoka H; Suzuki H; Higuchi K
J Clin Biochem Nutr; 2022 Mar; 70(2):189-196. PubMed ID: 35400818
[TBL] [Abstract][Full Text] [Related]
23. A case of paradoxical response during anti-tuberculosis treatment in a patient with ulcerative colitis.
Hosomi S; Sugita N; Kanamori A; Ominami M; Otani K; Kamata N; Tanaka F; Nagami Y; Taira K; Fujiwara Y
Clin J Gastroenterol; 2022 Jun; 15(3):592-597. PubMed ID: 35244861
[TBL] [Abstract][Full Text] [Related]
24. Effect of the Coronavirus Disease 2019 Lockdown on Lifestyle Factors in Japanese Patients with Inflammatory Bowel Disease.
Nishida Y; Hosomi S; Fujimoto K; Nakata R; Itani S; Ohminami M; Nadatani Y; Fukunaga S; Otani K; Tanaka F; Nagami Y; Taira K; Kamata N; Ohfuji S; Fujiwara Y
Intern Med; 2022 May; 61(9):1329-1336. PubMed ID: 35228418
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation.
Dumolard L; Aspord C; Marche PN; Macek Jilkova Z
Front Immunol; 2023; 14():1148111. PubMed ID: 37056774
[TBL] [Abstract][Full Text] [Related]
26. Soluble form of CTLA-4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients.
Teng W; Jeng WJ; Chen WT; Lin CC; Lin CY; Lin SM; Sheen IS
Cancer Med; 2022 Oct; 11(20):3786-3795. PubMed ID: 35435327
[TBL] [Abstract][Full Text] [Related]
27. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy.
Vlachogiannakos J; Papatheodoridis G
World J Gastroenterol; 2013 Dec; 19(47):8822-30. PubMed ID: 24379605
[TBL] [Abstract][Full Text] [Related]
28. Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment.
Kozuka R; Enomoto M; Dong MP; Hai H; Thuy LTT; Odagiri N; Yoshida K; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Tamori A; Kawada N
Sci Rep; 2022 Jan; 12(1):105. PubMed ID: 34996935
[TBL] [Abstract][Full Text] [Related]
29. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
30. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
Hiramatsu N; Yamada R; Takehara T
J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149
[TBL] [Abstract][Full Text] [Related]
31. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
[TBL] [Abstract][Full Text] [Related]
32. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
[TBL] [Abstract][Full Text] [Related]
33. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y
J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305
[TBL] [Abstract][Full Text] [Related]
34. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients.
Liang LY; Wong VW; Toyoda H; Tse YK; Yip TC; Yuen BW; Tada T; Kumada T; Lee HW; Lui GC; Chan HL; Wong GL
J Gastroenterol; 2020 Sep; 55(9):899-908. PubMed ID: 32556643
[TBL] [Abstract][Full Text] [Related]
35. Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment.
Xia J; Huang R; Chen Y; Liu Y; Wang J; Yan X; Zhang Z; Wu C
Aliment Pharmacol Ther; 2020 Jun; 51(11):1180-1187. PubMed ID: 32363582
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
